Dianthus Therapeutics, Inc. (DNTH)
Automate Your Wheel Strategy on DNTH
With Tiblio's Option Bot, you can configure your own wheel strategy including DNTH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DNTH
- Rev/Share 0.0814
- Book/Share 14.4587
- PB 2.532
- Debt/Equity 0.0024
- CurrentRatio 17.3475
- ROIC -0.2534
- MktCap 1325712680.0
- FreeCF/Share -2.9006
- PFCF -12.0929
- PE -10.9513
- Debt/Assets 0.0022
- DivYield 0
- ROE -0.3302
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | DNTH | Truist | -- | Buy | -- | $56 | Oct. 14, 2025 |
| Initiation | DNTH | William Blair | -- | Outperform | -- | -- | July 2, 2025 |
| Initiation | DNTH | TD Cowen | -- | Buy | -- | -- | Dec. 20, 2024 |
| Initiation | DNTH | Oppenheimer | -- | Outperform | -- | $48 | Oct. 3, 2024 |
News
Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Dianthus Therapeutics, Inc. (DNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing
Read More
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Dianthus Therapeutics, Inc. (DNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences:
Read More
About Dianthus Therapeutics, Inc. (DNTH)
- IPO Date 2018-06-21
- Website https://dianthustx.com
- Industry Biotechnology
- CEO Marino Garcia
- Employees 78